| Schedule of Segment Loss |
The following table sets forth our segment loss disclosure for the three and six months ended June 30, 2025 and 2024 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
R&D – Compensation and benefits (1) |
|
$ |
3,217 |
|
|
$ |
3,679 |
|
|
$ |
6,512 |
|
|
$ |
7,165 |
|
R&D – Clinical trial costs |
|
|
2,448 |
|
|
|
2,935 |
|
|
|
5,298 |
|
|
|
5,532 |
|
R&D – Outsourced services & consulting |
|
|
3,132 |
|
|
|
5,363 |
|
|
|
5,514 |
|
|
|
10,042 |
|
R&D – Lab and pharmacology supplies |
|
|
256 |
|
|
|
695 |
|
|
|
546 |
|
|
|
1,399 |
|
R&D – Other costs (2) |
|
|
440 |
|
|
|
465 |
|
|
|
1,036 |
|
|
|
898 |
|
G&A – Compensation and benefits (1) |
|
|
1,528 |
|
|
|
1,645 |
|
|
|
3,102 |
|
|
|
3,192 |
|
G&A – Professional service fees |
|
|
810 |
|
|
|
748 |
|
|
|
1,807 |
|
|
|
1,541 |
|
G&A – Insurance |
|
|
202 |
|
|
|
213 |
|
|
|
420 |
|
|
|
243 |
|
G&A – Other costs (3) |
|
|
618 |
|
|
|
595 |
|
|
|
1,344 |
|
|
|
967 |
|
Facilities related |
|
|
2,400 |
|
|
|
652 |
|
|
|
4,699 |
|
|
|
1,304 |
|
Stock-based compensation and depreciation |
|
|
2,010 |
|
|
|
2,401 |
|
|
|
4,124 |
|
|
|
3,991 |
|
Total operating expense |
|
|
17,061 |
|
|
|
19,391 |
|
|
|
34,402 |
|
|
|
36,274 |
|
Loss from operations |
|
|
(17,061 |
) |
|
|
(19,391 |
) |
|
|
(34,402 |
) |
|
|
(36,274 |
) |
Interest and other income, net |
|
|
1,386 |
|
|
|
2,415 |
|
|
|
2,969 |
|
|
|
3,868 |
|
Segment net loss |
|
$ |
(15,675 |
) |
|
$ |
(16,976 |
) |
|
$ |
(31,433 |
) |
|
$ |
(32,406 |
) |
(1)Excludes stock-based compensation expense. (2)Includes software expense, database subscriptions expense, lab service contract expense, travel expense, and other miscellaneous expenses. (3)Includes travel expense, public & investor relations expense, software expense, employee training & development expense, and other miscellaneous expenses.
|